Literature DB >> 8443626

Intrathecal baclofen in severe spasticity.

B N McLean1.   

Abstract

Control of severe spasticity and its associated features with administration of baclofen directly into the CSF via an intrathecal pump has radically improved the management of patients resistant to oral therapy. This article reviews the rationale and clinical indications for this technique, and the outcome and complications encountered.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8443626

Source DB:  PubMed          Journal:  Br J Hosp Med        ISSN： 0007-1064


  6 in total

Review 1.  Outcomes assessment of drug treatment in multiple sclerosis clinical trials.

Authors:  M Malone; B Lomaestro
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

2.  Long-term intrathecal baclofen therapy in ambulatory patients with spasticity.

Authors:  Saud A Sadiq; Gary C Wang
Journal:  J Neurol       Date:  2005-11-22       Impact factor: 4.849

Review 3.  Multiple sclerosis: symptomatic treatment.

Authors:  A J Thompson
Journal:  J Neurol       Date:  1996-08       Impact factor: 4.849

4.  Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity.

Authors:  B Middel; H Kuipers-Upmeijer; J Bouma; M Staal; D Oenema; T Postma; S Terpstra; R Stewart
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

Review 5.  Current pharmacologic treatment of multiple sclerosis symptoms.

Authors:  P B Andersson; D E Goodkin
Journal:  West J Med       Date:  1996-11

Review 6.  Progress in structure based drug design for G protein-coupled receptors.

Authors:  Miles Congreve; Christopher J Langmead; Jonathan S Mason; Fiona H Marshall
Journal:  J Med Chem       Date:  2011-06-15       Impact factor: 7.446
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.